Table 3.
Utility of OS‐related MiRNAs in cancer
| microRNA | Study type | Cancer type | Treatment drug | Therapy effect | References |
|---|---|---|---|---|---|
| miR‐34a | Mouse model | Prostate cancer | Systemically delivered miR‐34a mimics | Inhibited prostate cancer metastasis and extended survival time | 121 |
| Mouse model | Lung cancer | Systemically delivered miR‐34a mimics | A significant decrease in tumor burden | 127 | |
| Mouse model | Pancreatic cancer | A lipid‐based nanoparticle for systemic delivery with miR‐34a | Inhibited tumor growth | 128 | |
| Phase I clinical trial | Advanced solid tumors | A liposomal miR‐34a mimic, MRX34 | Showed evidence of antitumor activity | 129 | |
| Mouse model | Osteosarcoma | Delivery of miR‐34a mimics | Suppressed pulmonary metastases and tumor progression, and improved the overall survival | 131 | |
| miR‐155 | Mouse model | Lymphoma | Delivery with antimiR‐155 conjugated with a small peptide | Showed evidence of antitumor activity | 134 |
| miR‐221 | Mouse model | Hepatocellular carcinoma | Delivery with antimiR‐221 modified with cholesterol | Inhibited tumor growth and prolonged survival time | 135 |